1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis
- PMID: 20081802
- DOI: 10.1038/modpathol.2009.185
1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis
Abstract
In glial tumors, the loss of heterozygosity of the 1p and 19q chromosomal arms is thought to be a marker of good prognosis in oligodendroglial tumors. However, 1p and 19q loss of heterozygosity may be telomeric, interstitial, centromeric or affect the whole arm of the chromosome and the associations between these different patterns and tumor type, other molecular markers and patient prognosis remain unclear. We analyzed microsatellite markers in a region spanning the chromosome from the telomere to the centromere, to characterize the pattern of 1p and 19q loss of heterozygosity in 39 infiltrative gliomas, including astrocytomas, glioblastomas, oligoastrocytomas and oligodendrogliomas. We then studied the association between loss of heterozygosity and the expression of p53 protein and Olig2, as analyzed using immunohistochemistry, and epidermal growth factor receptor (EGFR) gene amplification, as investigated using fluorescence in situ hybridization (FISH). Finally, we assessed the influence of molecular markers on the overall survival of patients. We identified five different 1p19q loss of heterozygosity patterns among the tumors studied and found that loss of heterozygosity over the whole 1p arm was associated with loss of heterozygosity over the whole 19q arm in 90% of cases. 1p19q whole loss was present in all the classical oligodendrogliomas, whereas other 1p19q loss patterns predominated in oligoastrocytomas. 1p19q whole loss was also significantly associated with Olig2 overexpression, but was never observed in tumors overexpressing p53 protein. We also found that, among patients with contrast-enhancing tumors, those with 1p19q whole loss tended to survive for longer. In combination with classical histological and immunohistochemical data, 1p19q status determination provides pertinent information useful for (1) discriminating between histological types of gliomas and (2) identifying a subgroup of tumors that are associated with a better prognosis.
Similar articles
-
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.Clin Cancer Res. 2005 Feb 1;11(3):1119-28. Clin Cancer Res. 2005. PMID: 15709179
-
Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status.J Clin Pathol. 2011 Sep;64(9):793-801. doi: 10.1136/jcp.2010.087668. Epub 2011 Jun 8. J Clin Pathol. 2011. PMID: 21653654
-
[Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):752-8. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22335907 Chinese.
-
[Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):595-604. doi: 10.1016/j.neurol.2008.04.002. Epub 2008 May 21. Rev Neurol (Paris). 2008. PMID: 18565359 Review. French.
-
Molecular pathogenesis of malignant gliomas.Curr Opin Oncol. 1999 May;11(3):162-7. doi: 10.1097/00001622-199905000-00004. Curr Opin Oncol. 1999. PMID: 10328589 Review.
Cited by
-
Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis.World J Clin Cases. 2024 Sep 6;12(25):5739-5748. doi: 10.12998/wjcc.v12.i25.5739. World J Clin Cases. 2024. PMID: 39247740 Free PMC article.
-
Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis.J Neurooncol. 2012 Apr;107(2):281-8. doi: 10.1007/s11060-011-0757-4. Epub 2011 Nov 10. J Neurooncol. 2012. PMID: 22071792
-
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.Oncotarget. 2016 Oct 4;7(40):64615-64630. doi: 10.18632/oncotarget.11378. Oncotarget. 2016. PMID: 27556304 Free PMC article.
-
Expression of TCF7L2 in Glioma and Its Relationship With Clinicopathological Characteristics and Patient Overall Survival.Front Neurol. 2021 Jul 8;12:627431. doi: 10.3389/fneur.2021.627431. eCollection 2021. Front Neurol. 2021. PMID: 34305772 Free PMC article.
-
A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.Cell Mol Neurobiol. 2022 Apr;42(3):709-722. doi: 10.1007/s10571-020-00959-3. Epub 2020 Sep 7. Cell Mol Neurobiol. 2022. PMID: 32894375 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous